| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-TIGIT therapies for solid tumors: a systematic review
|
Rousseau, A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 2 |
Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline †
|
Grassi, L.
|
|
|
8 |
2 |
p.
|
artikel
|
| 3 |
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
|
Cortesi, L.
|
|
|
8 |
2 |
p.
|
artikel
|
| 4 |
A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system
|
Coolbrandt, A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 5 |
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
|
Villaruz, L.C.
|
|
|
8 |
2 |
p.
|
artikel
|
| 6 |
A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing
|
Paiella, S.
|
|
|
8 |
2 |
p.
|
artikel
|
| 7 |
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
|
Linardou, H.
|
|
|
8 |
2 |
p.
|
artikel
|
| 8 |
Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
|
Klempner, S.J.
|
|
|
8 |
2 |
p.
|
artikel
|
| 9 |
Clinical risk factors for ascites in metastatic pancreatic cancer
|
Berger, J.M.
|
|
|
8 |
2 |
p.
|
artikel
|
| 10 |
Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
|
Moliner, L.
|
|
|
8 |
2 |
p.
|
artikel
|
| 11 |
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”
|
Fumet, Jean-David
|
|
|
8 |
2 |
p.
|
artikel
|
| 12 |
Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy—results of a prospective, multicenter German observational study
|
Li, M.
|
|
|
8 |
2 |
p.
|
artikel
|
| 13 |
Editorial Board
|
|
|
|
8 |
2 |
p.
|
artikel
|
| 14 |
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors
|
Zheng, Y.
|
|
|
8 |
2 |
p.
|
artikel
|
| 15 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
|
Punt, C.J.A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 16 |
FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
|
Cervantes, A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 17 |
How I treat endocrine-dependent metastatic breast cancer
|
Gombos, A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 18 |
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
|
Amoroso, V.
|
|
|
8 |
2 |
p.
|
artikel
|
| 19 |
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)
|
Gridelli, C.
|
|
|
8 |
2 |
p.
|
artikel
|
| 20 |
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
|
de With, M.
|
|
|
8 |
2 |
p.
|
artikel
|
| 21 |
In the Literature: March 2023
|
Gambardella, V.
|
|
|
8 |
2 |
p.
|
artikel
|
| 22 |
Lenvatinib plus pembrolizumab a new effective combination of targeted agents
|
Perez-Fidalgo, J.A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 23 |
Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis
|
Palazzo, A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 24 |
Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
|
Dufresne, A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 25 |
Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors
|
Wang, R.
|
|
|
8 |
2 |
p.
|
artikel
|
| 26 |
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases
|
Hecht, J.R.
|
|
|
8 |
2 |
p.
|
artikel
|
| 27 |
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
|
Gouda, M.A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 28 |
Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline ☆
|
Stone, P.
|
|
|
8 |
2 |
p.
|
artikel
|
| 29 |
Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups
|
Saesen, R.
|
|
|
8 |
2 |
p.
|
artikel
|
| 30 |
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
|
Rudin, C.M.
|
|
|
8 |
2 |
p.
|
artikel
|
| 31 |
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
|
Sherman, E.
|
|
|
8 |
2 |
p.
|
artikel
|
| 32 |
Sex and gender perspectives in colorectal cancer
|
Baraibar, I.
|
|
|
8 |
2 |
p.
|
artikel
|
| 33 |
Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
|
Mulder, J.
|
|
|
8 |
2 |
p.
|
artikel
|
| 34 |
Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
|
Oing, C.
|
|
|
8 |
2 |
p.
|
artikel
|
| 35 |
Table of Contents
|
|
|
|
8 |
2 |
p.
|
artikel
|
| 36 |
The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial
|
Dijkstra, E.A.
|
|
|
8 |
2 |
p.
|
artikel
|
| 37 |
Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries
|
Post, H.C.
|
|
|
8 |
2 |
p.
|
artikel
|
Tijdschrift beschrijving